Peter Greenstreet

Peter Greenstreet

Auto-generated profile, based on publicly available information

Peter Greenstreet

Department of Mathematics and Statistics Lancaster University Lancaster UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2024 in Statistics in Medicine
Verified
Journal Article
Open access
PGPeter Greenstreet
Peter Greenstreet
TJThomas Jaki
Thomas Jaki
ABAlun Bedding
Alun Bedding
CHChris Harbron
Chris Harbron
PMPavel Mozgunov
Pavel Mozgunov
There is growing interest in platform trials that allow for adding of new treatment arms as the trial progresses as well as being able to stop treatments part way through the trial for either lack of benefit/futility or for superiority. In some situations, platform trials need to guarantee that error rates are controlled. This paper presents a multi‐stage design, that allows additional arms to be added in a platform trial in a preplanned fashion, while still controlling the family‐wise error rate, under the assumption of known number and timing of treatments to be added, and no time trends. A method is given to compute the sample size required to achieve a desired level of power and we show how the distribution of the sample size and the expected sample size can be found. We focus on power under the least favorable configuration which is the power of finding the treatment with a clinically relevant effect out of a set of treatments while the rest have an uninteresting treatment effect. A motivating trial is presented which focuses on two settings, with the first being a set number of stages per active treatment arm and the second being a set total number of stages, with treatments that are added later getting fewer stages. Compared to Bonferroni, the savings in the total maximum sample size are modest in a trial with three arms, <1% of the total sample size. However, the savings are more substantial in trials with more arms.

22 December 2024 in Biometrical Journal
Verified
Journal Article
Open access
PGPeter Greenstreet
Peter Greenstreet
TJThomas Jaki
Thomas Jaki
ABAlun Bedding
Alun Bedding
PMPavel Mozgunov
Pavel Mozgunov
There is a growing interest in the implementation of platform trials, which provide the flexibility to incorporate new treatment arms during the trial and the ability to halt treatments early based on lack of benefit or observed superiority. In such trials, it can be important to ensure that error rates are controlled. This paper introduces a multi‐stage design that enables the addition of new treatment arms, at any point, in a preplanned manner within a platform trial, while still maintaining control over the family‐wise error rate. This paper focuses on finding the required sample size to achieve a desired level of statistical power when treatments are continued to be tested even after a superior treatment has already been found. This may be of interest if there are treatments from different sponsors which are also superior to the current control or multiple doses being tested. The calculations to determine the expected sample size is given. A motivating trial is presented in which the sample size of different configurations is studied. In addition, the approach is compared to running multiple separate trials and it is shown that in many scenarios if family‐wise error rate control is needed there may not be benefit in using a platform trial when comparing the sample size of the trial.

2 April 2025 in Biometrics
Verified
Journal Article
Open access
PGPeter Greenstreet
Peter Greenstreet
TJThomas Jaki
Thomas Jaki
ABAlun Bedding
Alun Bedding
PMPavel Mozgunov
Pavel Mozgunov
Platform trials are an efficient way of testing multiple treatments. We consider platform trials where, if a treatment is found to be superior to the control, it will become the new standard of care. The remaining treatments are then tested against this new control. In this setting, one can either keep the information on both the new standard of care and the other active treatments before the control is changed or discard this information when testing for benefit of the remaining treatments. We show analytically and numerically, retaining the information collected before the change in control can be detrimental to the power in a frequentist multi-arm multi-stage trial. Specifically, we consider the overall power, the probability that the active treatment with the greatest treatment effect is found during the trial, and the conditional power, the probability a given treatment is found superior against the current control. Also studied is the conditional type I error, the probability a given treatment is incorrectly found superior against the current control. We prove when retaining the information decreases both the overall and conditional power but also decreases the conditional type I error. A motivating example is then studied. Based on these observations, we discuss different aspects to consider when deciding whether to run a continuous platform trial or run an inherently new trial using the same trial infrastructure.

6 October 2026 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
SPSameer Parpia
Sameer Parpia
PGPeter Greenstreet
Peter Greenstreet
TWTim Whelan
Tim Whelan
MLMark Levine
Mark Levine

14 August 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
Terry NgTerry Ng
Terry Ng
PGPeter Greenstreet
Peter Greenstreet
CSCarol Stober
Carol Stober
SNStuart G. Gordon Nicholls
Stuart G. Gordon Nicholls
JSJennifer Shamess
Jennifer Shamess
MCMark Clemons
Mark Clemons
Background: Granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, are associated with bone pain, potentially impacting treatment adherence. This study hypothesized that a 5-day regimen of filgrastim would result in less bone pain than single-dose pegfilgrastim in patients receiving chemotherapy for early breast cancer. Methods: In this multicenter, open-label, randomized controlled trial, patients requiring prophylactic G-CSF during chemotherapy were randomly assigned 1:1 to receive either 5-day filgrastim or pegfilgrastim. The primary outcome was patient-reported bone pain, assessed as area under the curve of daily pain scores (0 = no pain to 10 = worst pain) over the first 5 days following G-CSF in cycle 1. Secondary outcomes included bone pain in cycles 2-4, febrile neutropenia, hospitalizations, chemotherapy delays, dose reductions, early discontinuations, chemotherapy-related deaths, health-related quality of life, and health-care resource utilization. Results: From June 2021 to March 2023, a total of 233 patients were randomly assigned, with 219 analyzed (110 filgrastim and 109 pegfilgrastim) after excluding those who withdrew before receiving treatment. Adjusting for stratification factors and prespecified baseline covariates using repeated measures linear regression, the mean area under the curve (0-40) for cycle 1 bone pain was 10.2 (11.2) for 5-day filgrastim and 10.2 (9.81) for pegfilgrastim, with an adjusted mean difference of 0.70 (95% confidence interval = 1.62 to 3.02; P = .556). Although no clinically significant differences were observed in most secondary outcomes, the 5-day filgrastim group exhibited a numerically higher incidence of febrile neutropenia (6.4% vs 0.9%, P = .065) and hospitalization (10.0% vs 3.7%, P = .106). Conclusion: There was no significant difference in bone pain between 5-day filgrastim and pegfilgrastim.

8 October 2026 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PGPeter Greenstreet
Peter Greenstreet
Was not provided for this article.